Biosimilars

Biosimilars are a rapidly growing treatment option for physicians treating advanced diseases, with more than 20 unique biosimilars expected to enter the U.S. healthcare market over the next decade. Learn more about these safe and effective treatment options.

  • RESOURCE

    A Perfect Storm Brews for Biosimilar Marketing

    Dr. Robert Rifkin, Oncologist and McKesson’s Biosimilar Medical Director, shares his thoughts on why we are entering the perfect storm for biosimilar marketing due to the growing clinical acceptance and continued cost containment pressures.

 

Read below for biosimilar resources at every stage: biosimilar beginners, considerations when using biosimilars, and best practices post-adoption.

 

New to biosimilars?

  • Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from existing, FDA-approved reference biologics.
  • While biosimilars are similar to their reference biological product, they are not generic equivalents.
  • Biosimilars go through a rigorous FDA review process including analytical, animal and clinical studies.

Biosimilars go through an extensive FDA approval process and offer safe, effective therapeutic options for serious diseases

As more biosimilars become available in the U.S., providers, payers and patients all stand to benefit from further incorporating these safe and effective therapies throughout our healthcare ecosystem.

Rising healthcare costs, increasing drug production demands and reimbursement pressures are all putting a serious strain on our nation’s healthcare delivery system. By adopting biosimilars routinely into patient treatment decisions, we can improve overall access to critical, life-saving drugs all while reducing the costs of these expensive therapies through increased competition.

Learn more about the McKesson services available to support biosimilar and other practice needs by visiting our Solutions for Specialty Practices page.

Considering adopting biosimilars in your treatment regimens?

Biosimilars Currently Available through McKesson Include:

Biosimilar Drug

Biologic Reference Drug

HCPCS Code 

Patient Support Services

Full Prescribing Information

Zarxio
(filgrastim-sndz)

Neupogen

Q5101

Sandoz OneSource

FDA Drug Info (PDF, 3 MB)

Inflectra
(infliximab-dyyb)

Remicade

Q5103

Pfizer enCompass

FDA Drug Info (PDF, 1 MB)

Renflexis
(infliximab-abda)

Remicade

Q5104

Merck Access Program

FDA Drug Info (PDF, 537 KB)

Retacrit
(Epoetin alfa-epbx)

Epogen/Procrit

Q5105 (ESRD use)
Q5106 (non-ESRD use)

Pfizer enCompass

FDA Drug Info (PDF, 614 KB)

Fulphila
(pegfilgrastim-jmdb)

Neulasta

Q5108

Mylan Advocate Portal

FDA Drug Info (PDF, 921 KB)

Nivestym
(filgrastim-aafi)

Neupogen

Q5110

Pfizer enCompass

FDA Drug Info (PDF, 921 KB)

Udenyca
(pegfilgrastim-cbqv)

Neulasta

Q5111

Coherus COMPLETE | Support

FDA Drug Info (PDF, 1060 KB)

Mvasi
(bevacizumab-awwb)

Avastin

Q5107

Amgen Assist 360

FDA Drug Info (PDF, 627 KB)

Kanjinti
(trastuzumab-anns)

Herceptin

 

Amgen Assist 360

FDA Drug Info (PDF, 834 KB)

********* Embedded Contact Object*******